We are also aware that expression levels not necessarily reflect biological activities and our hypothesis that tumor expression pattern of steroidogenic AKR1C3 and constitutively active AR variants would predict response to 2nd line therapies of CRPC needs to be tested upfront in clinical studies. This evidence concerns the gene AR and neoplasm.